东宝生物(300239) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥138,178,161.95, representing a 53.56% increase compared to ¥89,993,866.50 in the same period last year[8] - Net profit attributable to shareholders was ¥4,628,670.64, up 36.59% from ¥3,508,687.40 in the previous year[8] - Basic and diluted earnings per share increased to ¥0.0089, reflecting a growth of 36.92% compared to ¥0.0067 in the previous year[8] - The company's net profit after deducting non-recurring gains and losses decreased by 10.31% year-on-year to CNY 2,282,380.49[23] - The net profit for the first quarter of 2021 was CNY 4,975,091.72, an increase of 76% compared to CNY 2,831,763.81 in the same period last year[63] - Operating profit reached CNY 6,343,741.66, up from CNY 3,525,775.07, reflecting a growth of 80% year-over-year[63] - The total profit amounted to CNY 6,347,193.29, compared to CNY 3,507,468.36 in the previous year, indicating a 81% increase[63] Cash Flow - The net cash flow from operating activities improved significantly to ¥3,278,714.69, a 209.95% increase from a negative cash flow of ¥2,350,379.61 in the same period last year[8] - Cash flow from operating activities generated a net amount of CNY 3,278,714.69, a significant recovery from a negative cash flow of CNY -2,982,028.40 in the prior year[67] - The net cash flow from investment activities was -11,965,847.06 CNY in Q1 2021, compared to -8,250,707.52 CNY in Q1 2020, indicating a decline in investment cash flow[71] - The net cash flow from financing activities was -8,059,928.22 CNY in Q1 2021, contrasting with a positive net cash flow of 18,883,375.32 CNY in Q1 2020[71] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,425,806,725.14, a slight increase of 0.56% from ¥1,417,934,200.36 at the end of the previous year[8] - Total liabilities increased to CNY 422,506,385.20 from CNY 419,750,969.84, reflecting a growth of about 0.60%[51] - The company's equity attributable to shareholders reached CNY 994,642,078.94, up from CNY 989,956,482.67, indicating an increase of approximately 0.17%[52] Shareholder Information - The total number of shareholders at the end of the reporting period was 30,374[12] - The largest shareholder, Inner Mongolia Dongbao Economic and Trade Co., Ltd., held 26.60% of the shares, totaling 138,823,422 shares[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Government Subsidies - The company received government subsidies amounting to ¥2,696,854.35, primarily related to asset-related government grants[9] - Cash received from government subsidies increased by 48.18% to CNY 2,599,306.80 compared to the previous period[22] Operational Costs and Expenses - The gross profit margin decreased due to a significant rise in operating costs, which amounted to ¥121,070,448.96, reflecting a 66.23% increase from ¥72,831,984.74[20] - Tax expenses increased by 79.48%, amounting to ¥2,181,946.29, due to higher sales leading to increased VAT and other taxes[20] - Selling expenses decreased by 39.30% to ¥2,135,151.99, as transportation costs were reclassified into operating costs under new revenue recognition standards[20] - Financial expenses surged by 135.50%, reaching ¥2,085,829.42, primarily due to increased interest on working capital loans[20] Future Outlook and Strategy - The company plans to continue expanding its product lines and market reach, focusing on gelatin and collagen products[20] - Future guidance indicates a positive outlook for revenue growth driven by increased sales volume and market demand[20] - The company plans to focus on innovation, operational strengthening, and new product promotion to drive growth[29] - The company aims to enhance product quality and development by collaborating with research institutions and downstream customers, focusing on new consumption trends and market expansion[31] Research and Development - The company is advancing the development of ultra-low endotoxin gelatin, aimed at applications in medical devices and tissue engineering[23] - A collaboration project with Shanghai Lanwei Medical Technology Co., Ltd. has been signed to expand the application of gelatin in high-value sectors[25] - The R&D project for artificial meat products has completed development, with a small production line in trial operation[27] - The company has initiated research on bioactive peptides derived from collagen, targeting applications in various fields[28] Production Capacity and Risks - The company has expanded its collagen production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions affecting full production ramp-up[30] - The company is addressing raw material procurement risks by optimizing supply chain management and exploring new sourcing channels[32] Compliance and Management - The company has received the "High-tech Enterprise Certificate" from relevant authorities, reaffirming its status as a high-tech enterprise[35] - The company is committed to improving its management efficiency and operational capabilities in response to the challenges posed by its expanded business scale[30] - The company has established a pandemic response team to mitigate the impact of COVID-19 on its operations and supply chain[34]